SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-326132
Filing Date
2020-12-23
Accepted
2020-12-23 17:01:01
Documents
13
Period of Report
2020-12-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d56889d8k.htm   iXBRL 8-K 31400
2 EX-10.1 d56889dex101.htm EX-10.1 74985
  Complete submission text file 0001193125-20-326132.txt   249102

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA xfor-20201221.xsd EX-101.SCH 3070
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE xfor-20201221_lab.xml EX-101.LAB 18888
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xfor-20201221_pre.xml EX-101.PRE 11860
6 EXTRACTED XBRL INSTANCE DOCUMENT d56889d8k_htm.xml XML 3476
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 201413320
SIC: 2836 Biological Products, (No Diagnostic Substances)